Moderna Shares Slide After Report of Delay on Kids’ Vaccine (2)

Oct. 15, 2021, 8:41 PM

Moderna Inc. shares fell after a report that U.S. regulators had put a decision on authorization of its Covid-19 shot for younger kids on hold over concerns about heart-related side effects.

Shares of the biotechnology company fell 2.3% to $324.21 at 4 p.m. on Friday in New York.

Read More: Sweden, Denmark Halt Moderna’s Covid Shot for Younger People

The Wall Street Journal reported, citing unidentified people familiar with the matter, that the Food and Drug Administration is delaying a decision on allowing younger people to receive the vaccine while it looks into whether it may lead to heightened ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.